Management of Covid-19 among Patients with Comorbid Cardiovascular Disease: A Scoping Review for Decreasing Mortality and Morbidity

Aan Nur'aeni, Hardianti Azhari Putri, Amalina Fildzah Fujilestari, Via Komalasari, Yulpiana Arunita, Atin Janatin, Lintang Tyas Ananda Riani Suara, Firdha Rizkiani Cipta Pertiwi

Abstract


Cardiovascular disease is comorbid with many Covid-19 patients, with Case Fatality Rate  (CFR) reaching 10.5%. The efforts made to reduce mortality and morbidity in Covid-19 patients with cardiovascular concomitant diseases are still being executed. This review aimed to identify the interventions and their relation to mortality and morbidity in these patients. This study is s scoping review, with databases used including Ebscohost, Goggle Scholar, Pubmed, and Proquest. This study using inclusion criteria: full-text and written in English.  It is using the keywords Cardiovascular disease, Covid-19, and Pharmacotherapy. Articles obtained totaling 145,680. Articles were sorted according to various restrictions, and various inclusion criteria obtained 18 articles. Several treatments can be used to reduce mortality in Covid-19 patients with CVD, they are: the administration of pharmacological drugs such as ACEI, ARB, RAAS inhibitors, and Hydroxychloroquine, statin, and advance cardiogenic shock treatment (MCS, V-A ECMO, and Impella). It discovered some effective treatments in lowering mortality rates. However, these results do not demonstrate consistency. So it is necessary to do more research. In addition, nurses need to develop nursing therapies that can synergize with medical therapies in improving the efficacy of treatment and lower mortality and morbidity in patients.

Full Text:

PDF

References


Referensi

Bravi, F., Flacco, M. E., Carradori, T., Volta, C. A., Cosenza, G., De Togni, A., Martellucci, C. A., Parruti, G., Mantovani, L., & Manzoli, L. (2020). Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens. PLoS ONE, 15(6 June), 1–11. https://doi.org/10.1371/journal.pone.0235248

Chatterjee, N. A., & Cheng, R. K. (2020). Cardiovascular disease and COVID-19: implications for prevention, surveillance and treatment.

Cheng, Biao (2020). Diagnosis And Treatment Strategy Of Coronavirus Disease 2019 With Cardiovascular Disease In Elderly Patients. Aging Medicine, 3(2), 95–97. doi:10.1002/agm2.12108

Chorin, E., Wadhwani, L., Magnani, S., Dai, M., Shulman, E., Nadeau-Routhier, C., Knotts, R., Bar-Cohen, R., Kogan, E., Barbhaiya, C., Aizer, A., Holmes, D., Bernstein, S., Spinelli, M., Park, D. S., Stefano, C., Chinitz, L. A., & Jankelson, L. (2020). QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm, 17(9), 1425–1433. https://doi.org/10.1016/j.hrthm.2020.05.014

Dan, S., Pant, M., & Upadhyay, S. K. (2020, December 1). The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. Current Pharmacology Reports. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s40495-020-00239-0

Dixon, D.L., et al. (2020). Cardiovascular Considerations inTreating Patients With Coronary Disease 2019 (Covid-19). Wolters Kluwer Health. Vol 07 No.05 Page 360-367.

Dworakowska.D & Grossman.A.B. (2020). Renin-Angiotensin System Inhibitors In Management Of Hypertension During The Covid-19 Pandemic. Journal Of Physiology And Pharmacology. 71, 2, 173-178 www.jpp.krakow.pl | DOI: 10.26402/jpp.2020.2.0

Guo, X., Zhu, Y., & Hong, Y. (2020). Decreased Mortality of COVID-19 with Renin–Angiotensin–Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis. American Heart Journal, 1–4.

Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020a). Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiology, 5(7), 825–830. https://doi.org/10.1001/jamacardio.2020.1624

Mehra, M.R., et al. (2020). Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. The New England Journal of Medicine. Page 1-8. DOI: 10.1056/NEJMoa2007621

Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., ... & Zhang, G. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging microbes & infections, 9(1), 757-760.

Prabhakaran, D., Perel, P., Roy, A., Singh, K., Raspail, L., Faria-Neto, J. R., Gidding, S. S., Ojji, D., Hakim, F., Newby, L. K., Stępińska, J., Lam, C. S. P., Jobe, M., Kraus, S., Chuquiure-Valenzuela, E., Piñeiro, D., Khaw, K.-T., Bahiru, E., Banerjee, A., … Sliwa, K. (2020). Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. Global Heart, 15(1), 44. https://doi.org/10.5334/gh.823

Rajagopal, K., Keller, S. P., Akkanti, B., Bime, C., Loyalka, P., Cheema, F. H., Zwischenberger, J. B., El Banayosy, A., Pappalardo, F., Slaughter, M. S., & Slepian, M. J. (2020). Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations from ASAIO - A Living Working Document. Circulation: Heart Failure. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007175

Qin, J. J., Cheng, X., Zhou, F., Lei, F., Akolkar, G., Cai, J., ... & Li, H. (2020). Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension, 76(4), 1104-1112.

Rey, J. R., Caro‐Codón, J., Rosillo, S. O., Iniesta, Á. M., Castrejón‐Castrejón, S., Marco‐Clement, I., … Buño, A. (2020). Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications. European Journal of Heart Failure, 22(12), 2205–2215. https://doi.org/10.1002/ejhf.1990

Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., … Huang, C. (2020). Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiology, 5(7), 802–810. https://doi.org/10.1001/jamacardio.2020.0950

Subir, Ray; Jagat J, Mukherjee; Kalyan K, Gangopadhyay (2020). Pros And Cons For Use Of Statins In People With Coronavirus Disease-19 (COVID-19). Diabetes & Metabolic Syndrome: Clinical Research & Reviews, (), S1871402120302599–. doi:10.1016/j.dsx.2020.07.011

Wang, J. J., Edin, M. L., Zeldin, D. C., Li, C., Wang, D. W., & Chen, C. (2020a). Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacology and Therapeutics, 215, 107628. https://doi.org/10.1016/j.pharmthera.2020.107628

WHO. (2021). WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. Retrieved February 26, 2021, from https://covid19.who.int/

Ye, Q., Lu, D., Shang, S., Fu, J., Gong, F., Shu, Q., & Mao, J. (2020). Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. ESC Heart Failure, 7(6), 3464–3472. https://doi.org/10.1002/ehf2.12960

Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J. J., Xie, J., Liu, Y. M., Zhao, Y. C., Huang, X., Lin, L., Xia, M., Chen, M. M., Cheng, X., Zhang, X., Guo, D., Peng, Y., Ji, Y. X., Chen, J., She, Z. G., Wang, Y., … Li, H. (2020). Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation research, 126(12), 1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.317134




DOI: https://doi.org/10.24198/pacnj.v2i2.32710

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Aan Nur'aeni



PACNJ is indexed on:
  </center>

Padjadjaran Acute Care Nursing Journal, Editorial Office:
Faculty of Nursing, Universitas Padjadjaran
Jl. Raya Bandung Sumedang KM.21, Hegarmanah, Kec. Jatinangor, Kabupaten Sumedang, Jawa Barat 45363


e-mail: info.pacnj@unpad.ac.id
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.